Sign In
Buy PLRX
$1.18
+0.0200 (+1.72%)
At Close: Jun 03, 2026
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
07:10pm, Friday, 22'nd May 2026
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
05:29pm, Thursday, 21'st May 2026
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant The
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
04:05pm, Monday, 11'th May 2026
First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confi
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
08:30am, Wednesday, 06'th May 2026
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-base
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication exp
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months Data highlighted in oral presentation at AACR's Clinical T
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Reduce” by Analysts
04:27am, Wednesday, 15'th Apr 2026
Shares of Pliant Therapeutics, Inc. (NASDAQ: PLRX - Get Free Report) have been assigned an average rating of "Reduce" from the five brokerages that are currently covering the company, Marketbeat.com r
Head-To-Head Review: Pliant Therapeutics (NASDAQ:PLRX) versus Dermata Therapeutics (NASDAQ:DRMA)
01:12am, Saturday, 21'st Mar 2026
Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) and Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-ba
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
04:05pm, Wednesday, 11'th Mar 2026
PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indicatio
Stock Picks From Seeking Alpha's February 2026 New Analysts
08:00am, Friday, 06'th Mar 2026
In February, we welcomed 17 new analysts to Seeking Alpha. This article showcases their stock picks and investment strategies. Analysts offered qualified investment opinions with detailed justificatio
Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration
01:28am, Tuesday, 24'th Feb 2026
Pliant Therapeutics trades at a deep discount to net cash after Bexotegrast's Phase 3 failure, with a $70M market cap versus $186M cash. Activist Kevin Tang holds 9.6%; given the 85%+ institutional ba
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
08:00am, Monday, 23'rd Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-bas
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Short Interest Up 21.0% in January
04:34am, Thursday, 05'th Feb 2026
Pliant Therapeutics, Inc. (NASDAQ: PLRX - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 3,
